GlassScriptPhysician profile
Kati Kaushal
NPI 1619452455
$721.55
in general payments reported to CMS, 2019-2025
11 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $182 · 2024: $122 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.55 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $258.05 | 2024-2025 | Activ.A.C., Snap, V.A.C. Dermatac |
| Molnlycke Health Care US, LLC | $205.53 | 2024-2025 | Mepilex Border Flex, Mextra Superabsorbant, Exufiber |
| Smith+Nephew, INC. | $65.20 | 2023-2024 | Collagenase Santyl, Grafix Pl, Oasis |
| Hartmann USA, INC. | $54.71 | 2023-2024 | Zetuvit Plus 10x10 P10, Zetuvit Plus |
| Next Science LLC | $34.88 | 2023 | Surgx, Blastx, Xperience |
| Kci USA, INC. | $25.01 | 2023 | Promogran Prisma, V.A.C. Dermatac, Kerramax Care |
| Abbott Laboratories | $18.88 | 2023 | Supera |
| Paratek Pharmaceuticals, INC. | $15.63 | 2025 | Nuzyra |
| Urgo Medical North America, LLC | $14.86 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Integra Lifesciences Corporation | $14.47 | 2023 | Tcc-Ez |
| Kerecis Limited | $14.33 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kati Kaushal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.